Aquestive Therapeutics - AQST Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings or view top-rated stocks.

5 brokers have issued 12-month price targets for Aquestive Therapeutics' stock. Their AQST share price forecasts range from $4.00 to $17.00. On average, they anticipate the company's stock price to reach $8.30 in the next year. This suggests a possible upside of 865.1% from the stock's current price.
View analysts price targets for AQST or view top-rated stocks among Wall Street analysts.

Aquestive Therapeutics' stock was trading at $0.9021 at the beginning of 2023. Since then, AQST shares have decreased by 4.7% and is now trading at $0.86.
View the best growth stocks for 2023 here.

Aquestive Therapeutics saw a drop in short interest in March. As of March 15th, there was short interest totaling 1,830,000 shares, a drop of 9.9% from the February 28th total of 2,030,000 shares. Based on an average daily trading volume, of 297,400 shares, the short-interest ratio is currently 6.2 days.
View Aquestive Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our AQST earnings forecast.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings results on Wednesday, March, 8th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The firm earned $10.68 million during the quarter, compared to analyst estimates of $9.93 million. During the same quarter in the prior year, the business posted ($0.38) EPS.

Aquestive Therapeutics issued an update on its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $37.00 million-$41.00 million, compared to the consensus revenue estimate of $37.83 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

(AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

Aquestive Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vahanian & Associates Financial Planning Inc. (1.25%), Schonfeld Strategic Advisors LLC (0.94%), Renaissance Technologies LLC (0.85%), Geode Capital Management LLC (0.72%), Millennium Management LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, John T Maxwell, Keith J Kendall, Lori J Braender and Peter E Boyd.
View institutional ownership trends.

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AQST stock can currently be purchased for approximately $0.86.

Aquestive Therapeutics (NASDAQ:AQST) has a market capitalization of $46.58 million and generates $47.68 million in revenue each year. The company earns $-54,410,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

The company employs 157 workers across the globe.

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The official website for the company is www.aquestive.com. The company can be reached via phone at (908) 941-1900 or via email at investorrelations@aquestive.com.